Publications
Peer Reviewed Publications on Replicor's NAP Technology
Pangenomic antiviral effect of REP 2139 in CRISPR/Cas9 engineered cell lines expressing hepatitis B virus surface antigen
Angelo A, Vaillant A, Blanchet M, Labonté P. PLoS One 2023; 18: e0293167
Rapid monophasic HBsAg decline during nucleic-acid polymer-based therapy predicts functional cure.
Herskovoich L, Shekhtman L, Bazinet M, Pantea V, Placinta G, Cotler SJ, Vaillant A, Dahari H. Hepatol Comm. 2023; 7: e0205
Novel fully automated prototype assays for specific detection of phosphorylated and non-phosphorylated Hepatitis B core antigens.
Geissler R, Patel M, Anderson M, Vaillant A, Qiu X, Cloherty G. J Clin Virol. 2023; 166: 105529
Bepirovirsen / GSK3389404: antisense or TLR9 agonists?
Vaillant A. Journal of Hepatology 2022; Sept 15.
Oligonucleotide-Based Therapies for Chronic HBV Infection: A Primer on Biochemistry, Mechanisms and Antiviral Effects
Vaillant A. Viruses 2022; 14: 2052
HBsAg isoform dynamics during NAP-based therapy of HBeAg-negative chronic HBV and HBV/HDV infection
Bazinet M, Anderson M, Pântea V, Placinta G, Moscalu I, Cebotarescu V, Cojuhari L, Jimbei P, Iarovoi L, Smesnoi V, Musteata T, Jucov A, Dittmer U, Gersch J, Holzmayer V, Kuhns M, Cloherty G, Vaillant A.
Hepatology Communications 2022, April 3
In vitro mechanistic evaluation of nucleic acid polymers: A cautionary tale
Vaillant A. Molecular Therapy Nucleic Acids 2022; 28: 168-174.
Analysis of HBsAg Immunocomplexes and cccDNA Activity During and Persisting After NAP-Based Therapy
Bazinet M, Anderson M, Pântea V, Placinta G, Moscalu I, Cebotarescu V, Cojuhari L, Jimbei P, Iarovoi L, Smesnoi V, Musteata T, Jucov A, Dittmer U, Gersch J, Holzmayer V, Kuhns M, Cloherty G, Vaillant A. Hepatology Communications 2021; July 10
Transaminase Elevations during Treatment of Chronic Hepatitis B Infection: Safety Considerations and Role in Achieving Functional Cure
Vaillant A. Viruses 2021 13: 745
Benefit of transaminase elevations in establishing functional cure of HBV infection during nap-based combination therapy
Bazinet M, Pântea V, , Placinta G, Moscalu I, Cebotarescu V, Cojuhari L, Jimbei P, Iarovoi L, Smesnoi V, Musteata T, Dittmer U, Krawczyk A, Vaillant A. Journal of Viral Hepatitis 2021; 5: 817-825
HBsAg, Subviral Particles, and Their Clearance in Establishing a Functional Cure of Chronic Hepatitis B Virus Infection
Vaillant A. ACS Infectious Diseases 2020 epub Dec 10
Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139‐Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection
Bazinet M, Pântea V, Cebotarescu V, Cojuhari L, Jimbei P, Anderson M, Gersch J, Holzmayer V, Elsner C, Krawczyk A, Kuhns MC, Cloherty G, Dittmer U, Vaillant A. Hepatology Communications 2020 5: 189-202
REP 301-LTF protocol
Characterization of the antiviral effects of REP 2139 on the HBV lifecycle in vitro
Boulon R, Blanchet M, Lemasson M, Vaillant A, Labonté P. Antiviral Research 2020 epub June 23 2020.
Shekhtman L, Cotler SJ, Hershkovich L, Uprichard SL, Bazinet M, Pantea V, Cebotarescu V, Cojuhari L, Jimbei P, Krawczyk A, Dittmer U, Vaillant A, Dahari H. Scientific Reports 2020; 10: 7837.
Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg
Shekhtman L, Cotler SJ, Hershkovich L, Uprichard SL, Bazinet M, Pantea V, Cebotarescu V, Cojuhari L, Jimbei P, Krawczyk A, Dittmer U, Vaillant A, Dahari H.
Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy
Bazinet M, Pântea V, Placinta P, Moscalu I, Cebotarescu V, Cojuhari L, Jimbei P, Iarovoi L, Smesnoi V, Musteata T, Jucov A, Dittmer U, Krawczyk A, Vaillant A. Gastroenterology 2020 epub Feb 5
REP 401 protocol
Kinetics of hepatitis B surface antigen quasispecies during REP 2139-Ca therapy in HBeAg positive chronic HBV infection.
Usman Z, Mijočević H, Karimzadeh H, Däumer M, Al-Mahtab M, Bazinet M, Frishman D, Vaillant A, Roggendorf M. Journal of Viral Hepatitis. epub July 19, 2019.
Inhibition of HBsAg secretion by nucleic acid polymers in HepG2.2.15 cells.
Blanchet M, Sinnathamby V, Vaillant A, Labonté P. Antiviral Research 2019 epub Feb 13, 2019.
Variants of hepatitis B virus surface antigen observed during therapy with nucleic acid polymer REP 2139-Ca have no influence on treatment outcome and its detection by diagnostic assays.
Mijočević H, Karimzadeh H, Seebach J, Usman Z, Mamun AM, Bazinet M, Vaillant A, Roggendorf M. Journal of Viral Hepatitis 2018 epub Nov 19, 2018.
REP 2139: Antiviral Mechanisms and Applications in Achieving Functional Control of HBV and HDV Infection.
Vaillant A. ACS Infectious Diseases 2018 epub Oct 8, 2018.
Nucleic acid polymer REP 2139 and nucleos(t)ide analogues act synergistically against chronic hepadnaviral infection in vivo.
Quinet J, Jamard C, Burtin M, Lemasson M, Guerret S, Sureau C, Vaillant A, Cova L. Hepatology 2017 epub Dec 18 2017.
Nucleic acid polymers are active against Hepatitis Delta Virus infection in vitro.
Beilstein F, Blanchet M, Vaillant A, Sureau C. Journal of Virology 2017 epub Dec 6 2017.
Activity of nucleic acid polymers in rodent models of HBV infection.
Schöneweis K, Motter N, Roppert PL, Lu M, Wang B, Roehl I, Glebe D, Yang D, Morrey JD, Roggendorf M, Vaillant A. Antiviral Research 2017 epub Nov 8, 2017.
Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial
Bazinet M, Pântea V, Cebotarescu V, Cojuhari L, Jimbei P, Albrecht J, Schmid P, Le Gal F, Gordien E, Krawczyk A, Mijočević H, Karimzadeh H, Roggendorf M, Vaillant A. The Lancet Gastroenterology & Hepatology 2017 epub Sept 27, 2017.
REP 301 study protocol
Inhibition of hepatitis B viral entry by nucleic acid polymers in HepaRG cells and primary human hepatocytes
Guillot C, Martel N, Berby F, Bordes I, Hantz O, Blanchet M, Sureau C, Vaillant A, Chemin I. PLOS ONE 2017 12: e0179697.
Nucleic Acid Polymers with Accelerated Plasma and Tissue Clearance for Chronic Hepatitis B Therapy.
Roehl I, Seiffert S, Brikh C, Quinet Q, Jamard C, Dorfler N, Lockridge JA, Cova L, Andrew Vaillant A. Mol Ther Nuc Acids. 2017 8: 1-12.
Nucleic acid-based polymers effective against hepatitis B Virus infection in patients don’t harbor immunostimulatory properties in primary isolated liver cells.
Real CI, Werner M, Paul A, Gerken G, Schlaak JF, Vaillant A, Broering B, Sci. Reports. 2017 7: 43838.
Nucleic acid polymers: Broad spectrum antiviral activity, antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection. Vaillant A. Antiviral Research 2016 133: 32-40.
Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection. Al-Mahtab M, Bazinet M, Vaillant A. PLOS ONE 2016 11: e0156667.
Therapeutic Antiviral Effect of the Nucleic Acid Polymer REP 2055 against Persistent Duck Hepatitis B Virus Infection. Noordeen F, Scougall CA, Grosse A, Qiao Q, Ajilian BB, Reache-Miller G, Finnie J, Werner M, Broering R, Schlaak J, Vaillant A, Jilbert AR. PLOS ONE 10: e0140909.
Nucleic acid polymers prevent the establishment of duck hepatitis B virus infection in vivo. Noordeen F, Vaillant A, Jilbert AR. Antimicrob Agents Chemother. 2013 57:5299-5306.
Nucleic acid polymers inhibit duck hepatitis B virus infection in vitro. Noordeen F, Vaillant A, Jilbert AR. Antimicrob Agents Chemother. 2013 57:5291-5298.
Amphipathic DNA polymers exhibit antiviral activity against systemic murine Cytomegalovirus infection. Cardin RD, Bravo FJ, Sewell AP, Cummins J, Flamand L, Juteau JM, Bernstein DI, Vaillant A. Virology Journal 2009, 6:214.
Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry. Matsumura T, Hu Z, Kato T, Dreux M, Zhang YY, Imamura M, Hiraga N, Juteau JM, Cosset FL, Chayama K, Vaillant A, Liang TJ. Gastroenterology. 2009 Aug;137(2):673-81.
Amphipathic DNA polymers exhibit antiherpetic activity in vitro and in vivo. Bernstein DI, Goyette N, Cardin R, Kern ER, Boivin G, Ireland J, Juteau JM, Vaillant A. Antimicrob Agents Chemother. 2008 Aug;52(8):2727-33.
Amphipathic DNA polymers are candidate vaginal microbicides and block herpes simplex virus binding, entry and viral gene expression. Guzman EM, Cheshenko N, Shende V, Keller MJ, Goyette N, Juteau JM, Boivin G, Vaillant A, Herold BC. Antivir Ther. 2007;12(8):1147-56. Erratum in: Antivir Ther. 2008;13(2):335.
Inhibition of cellular entry of lymphocytic choriomeningitis virus by amphipathic DNA polymers. Lee AM, Rojek JM, Gundersen A, Ströher U, Juteau JM, Vaillant A, Kunz S. Virology. 2008 Mar 1;372(1):107-17.
Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation. Vaillant A, Juteau JM, Lu H, Liu S, Lackman-Smith C, Ptak R, Jiang S. Antimicrob Agents Chemother. 2006 Apr;50(4):1393-401.